ClinicalTrials.gg
CompletedNCT00768560Updated Jun 8, 2015Results posted

Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study

A Phase 2 interventional study of Nifedipine (Adalat CR, BAYA1040) 80mg OD and Nifedipine (Adalat CR, BAYA1040) 40mg BID in Hypertension, sponsored by Bayer. Completed at 3 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-08.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.

Enrollment
23rd of 29
35 · median 72
Started
2008
with 2 others
Phase 2
3 of 29
none open now
Registered
6th of 29
by date
Lead sponsor
11 of 29
Bayer

Among the 29 studies testing nifedipine in Hypertension, this one is the 23rd largest by enrollment, is one of 3 that started in 2008, is one of 3 in phase 2, and was the 6th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nifedipine

Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing nifedipine in Hypertension, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, 6 x 3 cross-over study. All patients who meet the entry criteria will be required to stop taking any other anti-hypertensive agents than Adalat CR (controlled release), if taken, before starting 4 weeks (±7days) open-label Adalat CR 40 mg once daily (OD) treatment phase (baseline treatment period). Of them, those who are confirmed with their eligibility as subjects for the present study at the end of the baseline treatment period will be randomly allocated to one of the 6 treatment sequences on the basis of a computer-generated randomization list. Subsequently, BAY A1040 CR tablet 40 mg OD, 40 mg twice daily (BID) or 80 mg OD will be administered to a total of 6 weeks, 2 weeks per each treatment period (Period 1-3) under double-blind conditions using BAY A1040 CR tablet 40 mg and its placebo as follows (Double-blind treatment period).

Read the detailed description

Issues on safety are addressed in the Adverse Event section.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female
  • 20 years or older and less than 75 years
  • Outpatient
  • Untreated or treated patients with antihypertensive agents whose blood pressure (BP) in sitting position at entry (Visit 1) is as follows.

    • Untreated patients: systolic blood pressure (SBP) >= 160mmHg or diastolic blood pressure (DBP) >= 100mmHg
    • Treated patients: SBP >= 140mmHg or DBP >= 90mmHg (at trough)

Exclusion criteria

Exclusion Criteria:

  • Patients whose BP during baseline treatment period is: SBP>=200mmHg or DBP>=120mmHg.
  • Patients with secondary hypertension or hypertensive emergency.
  • Patients with cardiovascular or cerebrovascular ischemic event (stroke, (TIA), myocardial infarction or unstable angina), or with history of these within 6 months prior to the study.
  • Patients with intracranial or subarachnoid hemorrhage, or with history of these within 6 months prior to the study.
  • Patients with server hematopoietic dysfunction (acute/chronic leukemia, myeloma, malignant lymphoma, myelodysplastic syndrome, aplastic anemia), or with history of these.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Active comparator
    Nifedipine (Adalat CR, BAYA1040) 40 mg OD

    Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning

    Drug: Nifedipine (Adalat CR, BAYA1040) 40mg OD

  • Experimental
    Nifedipine (Adalat CR, BAYA1040) 40 mg BID

    Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening

    Drug: Nifedipine (Adalat CR, BAYA1040) 40mg BID

  • Experimental
    Nifedipine (Adalat CR, BAYA1040) 80 mg OD

    Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning

    Drug: Nifedipine (Adalat CR, BAYA1040) 80mg OD

Interventions

06

What researchers measure

Primary outcomes

  1. Change of Sitting Blood Pressure

    Changes of sitting SBP and DBP (trough values) from baseline (ie \[trough BP at the end of each period during the double-blind treatment period\] minus \[trough BP at the end of the baseline treatment period\])

    Time frame: Baseline and after 2 weeks treatment

Secondary outcomes

  1. Differences of Systolic Blood Pressure Profile

    Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)

    Time frame: Baseline and after 2 weeks treatment

  2. Differences of Diastolic Blood Pressure Profile

    Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)

    Time frame: Baseline and after 2 weeks treatment

  3. Target Blood Pressure Achievement in Elderly (≥65)

    Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg

    Time frame: After 2 weeks treatment

  4. Target Blood Pressure Achievement in Non-elderly (<65)

    Non-elderly subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg

    Time frame: After 2 weeks treatment

  5. Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder

    Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg

    Time frame: After 2 weeks treatment

  6. Target Blood Pressure Achievement in All Subjects

    Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg. Subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg.

    Time frame: After 2 weeks treatment

07

Results

Posted Feb 2, 2010

Participant flow

47 subjects were recruited from 30 Jan 2008 to 11 May 2008 by 3 centers in Japan.

Intervention Set 1
Participant flow — Intervention Set 1
MilestoneNifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each
Started566666
Subjects received treatment566666
Completed556666
Not completed010000
Withdrew: Adverse event010000
Intervention Set 2
Participant flow — Intervention Set 2
MilestoneNifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each
Started556666
Completed556666
Not completed000000
Intervention Set 3
Participant flow — Intervention Set 3
MilestoneNifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each
Started556666
Completed556666
Not completed000000

Outcome measures

PrimaryChange of Sitting Blood Pressure

Changes of sitting SBP and DBP (trough values) from baseline (ie \[trough BP at the end of each period during the double-blind treatment period\] minus \[trough BP at the end of the baseline treatment period\])

Time frame:
Baseline and after 2 weeks treatment
Reported as:
Least squares mean · mm Hg
Change of Sitting Blood Pressure
mm HgNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
Systolic Blood Pressure-10.19 ± 1.24-19.88 ± 1.24-10.13 ± 1.24
Diastolic Blood Pressure-4.30 ± 0.65-8.28 ± 0.65-4.98 ± 0.65
Statistical analysis
  • Nifedipine (Adalat CR, BAYA1040) 40 mg OD vs Nifedipine (Adalat CR, BAYA1040) 40 mg BID · Mean difference (final values): -9.69 · 90% CI -12.62 to -6.7740 mg BID minus 40 mg OD
  • Nifedipine (Adalat CR, BAYA1040) 40 mg OD vs Nifedipine (Adalat CR, BAYA1040) 80 mg OD · Mean difference (final values): 0.06 · 90% CI -2.87 to 2.9880 mg OD minus 40 mg OD
  • Nifedipine (Adalat CR, BAYA1040) 40 mg BID vs Nifedipine (Adalat CR, BAYA1040) 80 mg OD · Mean difference (final values): 9.75 · 90% CI 6.83 to 12.6780 mg OD minus 40 mg BID
  • Nifedipine (Adalat CR, BAYA1040) 40 mg OD vs Nifedipine (Adalat CR, BAYA1040) 40 mg BID · Mean difference (final values): -3.97 · 90% CI -5.50 to -2.4440 mg BID minus 40 mg OD
  • Nifedipine (Adalat CR, BAYA1040) 40 mg OD vs Nifedipine (Adalat CR, BAYA1040) 80 mg OD · Mean difference (final values): -0.68 · 90% CI -2.21 to 0.8580 mg OD minus 40 mg OD
  • Nifedipine (Adalat CR, BAYA1040) 40 mg BID vs Nifedipine (Adalat CR, BAYA1040) 80 mg OD · Mean difference (final values): 3.29 · 90% CI 1.76 to 4.8280 mg OD minus 40 mg BID
SecondaryDifferences of Systolic Blood Pressure Profile

Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)

Time frame:
Baseline and after 2 weeks treatment
Reported as:
Mean · mm Hg
Differences of Systolic Blood Pressure Profile
mm HgNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
At 0-hour post-dose-11.35 ± 15.75-21.24 ± 11.56-9.91 ± 10.58
At 2-hour post-dose-4.91 ± 11.62-8.65 ± 11.19-11.97 ± 10.15
At 4-hour post-dose-6.18 ± 12.05-5.76 ± 11.25-7.85 ± 10.02
At 6-hour post-dose-6.56 ± 12.58-4.94 ± 9.31-7.26 ± 8.40
At 8-hour post-dose-7.88 ± 11.53-6.97 ± 10.23-7.88 ± 10.68
At 10-hour post-dose-4.79 ± 10.60-4.03 ± 10.64-6.56 ± 9.41
At 12-hour post-dose-5.59 ± 10.98-4.38 ± 9.31-6.00 ± 9.98
At 24-hour post-dose-8.97 ± 12.79-18.38 ± 8.34-10.21 ± 10.87
SecondaryDifferences of Diastolic Blood Pressure Profile

Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)

Time frame:
Baseline and after 2 weeks treatment
Reported as:
Mean · mm Hg
Differences of Diastolic Blood Pressure Profile
mm HgNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
At 0-hour post-dose-3.82 ± 6.40-8.12 ± 6.24-4.18 ± 5.54
At 2-hour post-dose-4.15 ± 7.27-5.47 ± 7.01-7.18 ± 5.89
At 4-hour post dose-3.44 ± 7.47-1.62 ± 8.11-3.68 ± 6.33
At 6-hour post-dose-5.56 ± 7.42-1.71 ± 7.20-3.85 ± 5.94
At 8-hour post dose-3.09 ± 6.13-3.18 ± 6.26-4.74 ± 6.30
At 10-hour post-dose-2.24 ± 6.34-1.74 ± 6.42-3.82 ± 7.26
At 12-hour post-dose-2.47 ± 6.59-2.15 ± 7.30-3.15 ± 6.97
At 24-hour post dose-5.00 ± 7.34-8.47 ± 5.39-5.82 ± 8.18
SecondaryTarget Blood Pressure Achievement in Elderly (≥65)

Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg

Time frame:
After 2 weeks treatment
Reported as:
Number · participants
Target Blood Pressure Achievement in Elderly (≥65)
participantsNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
Target Blood Pressure Achievement in Elderly (≥65)233
SecondaryTarget Blood Pressure Achievement in Non-elderly (<65)

Non-elderly subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg

Time frame:
After 2 weeks treatment
Reported as:
Number · participants
Target Blood Pressure Achievement in Non-elderly (<65)
participantsNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
Target Blood Pressure Achievement in Non-elderly (<65)3104
SecondaryTarget Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder

Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg

Time frame:
After 2 weeks treatment
Reported as:
Number · participants
Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder
participantsNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder041
SecondaryTarget Blood Pressure Achievement in All Subjects

Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP \<140 mm Hg and DBP \<90 mm Hg. Subjects (\<65 years) without diabetes mellitus or chronic renal disorder and target BP SBP \<130 mm Hg and DBP \<85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP \<130 mm Hg and DBP \<80 mm Hg.

Time frame:
After 2 weeks treatment
Reported as:
Number · participants
Target Blood Pressure Achievement in All Subjects
participantsNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
Target Blood Pressure Achievement in All Subjects5178

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nifedipine (Adalat CR, BAYA1040) 40 mg OD—0/35 (0%)5/35 (14.3%)
Nifedipine (Adalat CR, BAYA1040) 40 mg BID—0/34 (0%)7/34 (20.6%)
Nifedipine (Adalat CR, BAYA1040) 80 mg OD—0/34 (0%)5/34 (14.7%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventNifedipine (Adalat CR, BAYA1040) 40 mg ODNifedipine (Adalat CR, BAYA1040) 40 mg BIDNifedipine (Adalat CR, BAYA1040) 80 mg OD
AnaemiaBlood and lymphatic system disorders2/350/342/34
NasopharyngitisInfections and infestations0/352/340/34
Stomach discomfortGastrointestinal disorders0/351/340/34
Blood albumin decreasedInvestigations1/351/340/34
Blood alkaline phosphatase increasedInvestigations0/351/340/34
Blood creatine phosphokinase increasedInvestigations0/350/341/34
Blood triglycerides increasedInvestigations0/351/340/34
Haematocrit decreasedInvestigations0/351/341/34
White blood cell count decreasedInvestigations0/350/341/34
Lipid metabolism disorderMetabolism and nutrition disorders1/351/340/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks EachTotal
Mean61.4 (55 to 68)63.6 (55 to 73)59.7 (55 to 65)64.3 (60 to 70)58.2 (37 to 67)59.7 (56 to 68)61.1 (37 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks EachTotal
Female1302118
Male42645526
Blood Pressure (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) at Baseline
Blood Pressure (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) at Baseline(mm Hg)Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks EachTotal
SBP at baseline150.00 ± 7.91161.00 ± 16.67156.33 ± 11.18155.83 ± 10.96156.33 ± 14.79154.83 ± 13.53155.89 ± 12.38
DBP at baseline94.40 ± 4.9895.00 ± 6.6098.00 ± 6.4591.00 ± 7.0792.50 ± 3.4589.83 ± 7.6893.43 ± 6.40
Heart rate (HR) at Baseline
Heart rate (HR) at Baseline(beats / min)Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks EachNifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks EachNifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks EachNifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks EachNifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks EachNifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks EachTotal
Mean64.20 ± 6.1872.67 ± 13.9579.00 ± 10.8170.83 ± 5.4268.50 ± 7.8779.50 ± 17.8472.69 ± 11.83
08

Study locations

3 sites
  • Sendai, Miyagi 982-0032, Japan
  • Suita, Osaka 565-0853, Japan
  • Koshigaya, Saitama 343-0827, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2008
First posted
Oct 8, 2008
Start
Jan 2008
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Feb 2, 2010
Last update
Jun 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00768560
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 8, 2008
Start date
Jan 2008
Primary completion
May 2008
Completion
May 2008
Results posted
Feb 2, 2010
Last update
Jun 8, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion